Ishani Therapeutics: Valuing a Deal Custom Case Solution & Analysis

Evidence Brief: Ishani Therapeutics

1. Financial Metrics

Category	Data Point	Source
Upfront Payment	25 million dollars	Exhibit 1
Development Milestones	100 million dollars total	Exhibit 1
Royalty Rate	15 percent of net sales	Exhibit 1
Internal Phase III Cost	80 million dollars	Paragraph 14
Probability of Success (PoS)	30 percent for Phase III	Exhibit 4
Peak Annual Sales	850 million dollars	Exhibit 5
Discount Rate (Biotech)	15 percent	Paragraph 22
Cash Runway	14 months remaining	Paragraph 8

2. Operational Facts

Lead asset IT-101 targets a rare autoimmune disorder with no current FDA approved therapy.
Manufacturing requires specialized biologic processing currently outsourced to a third party.
Clinical trial recruitment requires 45 centers across North America and Europe.
Regulatory submission timeline spans 18 to 24 months post Phase III completion.

3. Stakeholder Positions

Dr. Ishani: Founder and CEO. Favors internal development to maximize long term equity value but recognizes capital constraints.
Venture Capital Board Members: Pressuring for a liquidity event or a derisking partnership to protect the current 45 million dollar investment.
Global Pharma: The potential partner. Seeking to fill a gap in their immunology pipeline before a major patent cliff.

4. Information Gaps

Specific termination clauses in the Global Pharma contract are not detailed.
Competitor Phase II data for a similar compound is mentioned but the specific efficacy delta is absent.
The exact cost of the outsourced manufacturing scale-up for commercial launch remains an estimate.

Strategic Analysis

1. Core Strategic Question

Should Ishani Therapeutics accept the licensing deal from Global Pharma now or fund Phase III internally to capture higher terminal value?
Can the firm survive the binary risk of Phase III failure without a partner?

2. Structural Analysis

The decision hinges on the Risk-Adjusted Net Present Value (rNPV). Internal development offers a higher potential payoff but carries a 70 percent chance of total capital loss. The current cash runway of 14 months is insufficient to cover the 36 month Phase III timeline.

Porter Five Forces Application: The threat of substitutes is low due to the orphan drug status of IT-101. However, the bargaining power of buyers (Big Pharma) is high because Ishani lacks the capital to commercialize independently.

3. Strategic Options

Option A: License to Global Pharma immediately. This provides 25 million dollars in non-dilutive capital and shifts all Phase III costs and risks to the partner. Trade-off: Limits upside to royalties and milestones.
Option B: Go Solo through Phase III. Requires a massive equity raise (approximately 100 million dollars) at a high cost of capital. Trade-off: Maximum value retention but extreme risk of bankruptcy if the trial fails.
Option C: Seek a Co-Development Deal. Share costs and profits 50/50. Trade-off: Higher complexity in decision making and slower execution.

4. Preliminary Recommendation

Execute the licensing deal with Global Pharma. The financial gap between the current runway and Phase III requirements makes internal development a gamble rather than a strategy. The 25 million dollar upfront payment secures the solvency of the firm while the 15 percent royalty provides significant participation in the success of the drug.

Implementation Roadmap

1. Critical Path

Month 1: Finalize legal due diligence and sign the definitive agreement with Global Pharma.
Month 2 to 3: Execute technology transfer of the biologic manufacturing process to the Global Pharma internal facility.
Month 4: Transition clinical trial management to the Global Pharma regulatory team.
Month 6: Receive the first development milestone payment upon successful trial site initiation.

2. Key Constraints

Regulatory Alignment: Any delay in FDA feedback on the Phase III protocol will stall the first milestone payment.
Data Integrity: The transfer of Phase II data must be seamless to avoid a re-audit by Global Pharma.

3. Risk-Adjusted Implementation Strategy

The plan assumes a 20 percent buffer in the timeline for tech transfer. If the manufacturing scale-up fails at the Global Pharma site, Ishani must retain the right to use its original third-party vendor to prevent a breach of contract.

Executive Review and BLUF

1. BLUF

Accept the Global Pharma offer immediately. Ishani Therapeutics faces a terminal capital gap within 14 months. Internal development requires 80 million dollars that the firm does not have and cannot raise without massive dilution. Partnering derisks the asset, secures the balance sheet, and provides a clear path to commercialization. This is a binary choice between a guaranteed 25 million dollar infusion and a 70 percent probability of corporate liquidation.

2. Dangerous Assumption

The analysis assumes Global Pharma will prioritize IT-101. If Global Pharma acquires a competing asset, they may shelve IT-101 to protect their internal pipeline, leaving Ishani with an orphaned drug and no remaining runway.

3. Unaddressed Risks

Integration Friction: The loss of key scientific talent during the transition to Global Pharma could degrade the quality of clinical oversight. Probability: High. Consequence: Delayed approval.
Royalty Compression: Future healthcare policy changes may cap the pricing of orphan drugs, significantly reducing the 15 percent royalty value. Probability: Moderate. Consequence: Lower terminal value.

4. Unconsidered Alternative

The team failed to consider a regional licensing strategy. Ishani could license Asian and European rights to separate partners while retaining North American rights. This would generate immediate cash while preserving the most valuable market for internal development or a later, higher-value sale.